New oral peptide therapy aims to protect kidneys in chronic disease

NCT ID NCT07187713

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 37 times

Summary

This study tests a liquid medication called ACE Reno, taken under the tongue four times a day for 12 weeks, in 300 adults with kidney damage from diabetes, high blood pressure, autoimmune diseases, or other causes. The goal is to see if it can reduce protein in the urine and help keep kidney function stable. Participants must already be on standard treatments like blood pressure or diabetes medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (STAGE 3-4) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • British Centre For Regenerative medicine BCRMED Global

    RECRUITING

    Giza, GZ, 12311, Egypt

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.